Abstract:BACKGROUND:Insulin-like growth factor-I receptor (IGFIR) has been shown to regulate the tumor development. The objective of the current study is to determine the association of IGFIR with lymph node metastasis and to explore the related mechanism in human colorectal cancer in clinic.METHODS:In a random series of 98 colorectal cancer patients, the expressions of IGFIR, vascular endothelial growth factor (VEGF) and VEGF-C were investigated by immunohistochemistry, and the association of these expressions with lymph node metastasis was statistically analyzed. The expressions of VEGF and VEGF-C in colorectal cancer cells stimulated with IGF-I were also examined by real-time quantitative reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay.RESULTS:Higher rates of IGFIR (46%), VEGF (53%), and VEGF-C (46%) expression were found in colorectal cancer tissues than in normal and colorectal adenoma tissues. These expressions were significantly associated with clinicopathologic factors and lymph node status. We also found the concomitant high expressions of IGFIR/VEGF (P < 0.001) and IGFIR/VEGF-C (P = 0.001) had a stronger correlation with lymph node metastasis than did each alone or both low expressions. In addition, IGF-I could effectively induce the VEGF and VEGF-C mRNA expression and protein secretion in colorectal cancer cells expressing IGFIR molecules. Moreover, Patients who had strong staining for IGFIR, VEGF and VEGF-C showed significantly less favorable survival rates compared with patients who had low staining for these molecules (P < 0.001). The survival rates of patients who were both high expression of IGFIR/VEGF and IGFIR/VEGF-C also were significantly lower compared with patients who were negative or one of high expression of these molecules (P < 0.001).CONCLUSIONS:Together the findings indicated for the first time that simultaneous examination of the expressions of IGFIR, VEGF and VEGF-C will benefit the diagnosis of lymph node metastasis in order to assay the prognosis and determine the treatment strategy in patients with colorectal cancer undergoing surgery.

[Expression and clinical significance of IGF-II mRNA and bcl-2 protein in colorectal adenocarcinomas].

IGF-II Promotes the Proliferation and Apoptosis of Human Colorectal Adenocarcinomas and Its Clinical Significance

Expression of Survivin and Its Correlation with Expression of Bcl-2 and P53 in Colorectal Adenocarcinoma

[Expression and Significance of Bmi-1 and Ki67 in Colorectal Carcinoma Tissues].

Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma

Expression and Clinical Significance of IGF-I and IGF-IR in Colorectal Cancer

Expression and clinical significances of Beclin1 and Bcl-2 in colon cancer

Expression of E2F-1 and Bcl-2 in Human Colorectal Carcinoma and Their Clinical Significance.

Expression of BMP-2 and its significance in colorectal cancer

Expression and Significance of P53 and Bcl-2 Protein Pancreatic Adenocarcinoma

The Expression of Bcl-2,Bcl-xL and Bax Protein in Colorectal Carcinomas

Expression of Bcl-2,Bcl-x_L and Bax in colorectal carcinomas

Genomic Imprinting of Insulin-Like Growth Factorii in Colorectal Cancer and Its Relationship with the Presence of Metastasis

Cellular apoptosis, proliferation and bcl-2 Bax expression in colorectal carcinoma and their association with tumor prognosis]

Expression of insulin-like growth factor-Ⅰ receptor in colorectal polypus and its clinical significance

Elevated IGFIR Expression Regulating VEGF and VEGF-C Predicts Lymph Node Metastasis in Human Colorectal Cancer.

[Expression of Matrix Metalloproteinase-2 and Insulin-Like Growth Factor-1 in Gastric Carcinoma and Their Clinicopathological Significance].

High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis

Expression of COX-2 and bFGF in Cervical Carcinoma and Its Clinical Significance

Expressions of P53 and Bcl-2 in Pancreatic Carcinoma and Its Clinical Significance

Coexpression of Myc and Bcl-2 Predicts Prognosis in Primary Gastrointestinal Diffuse Large B-Cell Lymphoma